Effect of bariatric surgery on heart failure

Expert Review of Cardiovascular Therapy

Volumn 15, Issue 8, 2017, Pages 567-579

  Rodriguez Flores, Marcela ^a   Aguilar Salinas, Carlos ^a   Piché, Marie Eve ^b,c   Auclair, Audrey ^b   Poirier, Paul ^b,c  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

bariatric surgery; heart failure; morbidity; mortality; Severe obesity

Indexed keywords

NATRIURETIC FACTOR;

BARIATRIC SURGERY; CARDIAC MUSCLE; CARDIAC PATIENT; DISEASE SEVERITY; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; META ANALYSIS (TOPIC); MOLECULAR DIAGNOSIS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; CARDIOMYOPATHY; COMPLICATION; FEMALE; HEART LEFT VENTRICLE FUNCTION; MALE;

BARIATRIC SURGERY; CARDIOMYOPATHIES; FEMALE; HEART FAILURE; HUMANS; MALE; OBESITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85026763268     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1080/14779072.2017.1352471     Document Type: Review

References (145)

1. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity among adults:United States, 2011-2012. NCHS Data Brief. 2013;(131):1–8. Available from:https://www.cdc.gov/nchs/data/databriefs/db131.pdf.
2. Poirier P, Alpert MA, Fleisher LA, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery:a science advisory from the American Heart Association. Circulation. 2009;120:86–95.
3. Lewis CE, McTigue KM, Burke LE, et al. Mortality, health outcomes, and body mass index in the overweight range:a science advisory from the American Heart Association. Circulation. 2009;119:3263–3271.
4. Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary:heart disease and stroke statistics–2012 update:a report from the American Heart Association. Circulation. 2012;125:188–197.
5. Rheaume C, Leblanc ME, Poirier P., Adiposity assessment:explaining the association between obesity, hypertension and stroke. Expert Rev Cardiovasc Ther. 2011;9:1557–1564.
6. Bastien M, Poirier P, Lemieux I, et al. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56:369–381.
7. Poirier P, Cornier MA, Mazzone T, et al. Bariatric surgery and cardiovascular risk factors:a scientific statement from the American Heart Association. Circulation. 2011;123:1683–1701.
8. Cornier MA, Despres JP, Davis N, et al. Assessing adiposity:a scientific statement from the American Heart Association. Circulation. 2011;124:1996–2019.
9. McMurray JJ, Petrie MC, Murdoch DR, et al. Clinical epidemiology of heart failure:public and private health burden. Eur Heart J. 1998;19(Suppl):P:9-16.
10. Teng TH, Finn J, Hobbs M, et al. Heart failure:incidence, case fatality, and hospitalization rates in Western Australia between 1990 and 2005. Circ Heart Fail. 2010;3:236–243.
11. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–1402.
12. Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr. 2012;10:22.
13. Schocken DD, Benjamin EJ, Fonarow GC, et al. Prevention of heart failure:a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117:2544–2565.
14. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–313.
15. Alpert MA, Terry BE, Mulekar M, et al. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol. 1997;80:736–740.
16. Aune D, Sen A, Norat T, et al. Body mass index, abdominal fatness, and heart failure incidence and mortality:a systematic review and dose-response meta-analysis of prospective studies. Circulation. 2016;133:639–649.
17. Bazzano LA, Belame SN, Patel DA, et al. Obesity and left ventricular dilatation in young adulthood:the Bogalusa Heart Study. Clin Cardiol. 2011;34:153–159.
18. Shah RV, Abbasi SA, Heydari B, et al. Insulin resistance, subclinical left ventricular remodeling, and the obesity paradox:MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013;61:1698–1706.
19. Yeboah J, Bluemke DA, Hundley WG, et al. Left ventricular dilation and incident congestive heart failure in asymptomatic adults without cardiovascular disease:multi-ethnic study of atherosclerosis (MESA). J Card Fail. 2014;20:905–911.
20. Waring ME, Saczynski JS, McManus D, et al. Weight and mortality following heart failure hospitalization among diabetic patients. Am J Med. 2011;124:834–840.
21. Curtis JP, Selter JG, Wang Y, et al. The obesity paradox:body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005;165:55–61.
22. Hu G, Jousilahti P, Antikainen R, et al. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010;121:237–244.
23. Clark AL, Fonarow GC, Horwich TB. Waist circumference, body mass index, and survival in systolic heart failure:the obesity paradox revisited. J Card Fail. 2011;17:374–380.• Differences between BMI and body composition when assessing cardiovascular risk and disease.
24. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease:pathophysiology, evaluation, and effect of weight loss:an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism. Circulation. 2006;113:898–918.
25. Lavie CJ, Alpert MA, Arena R, et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1:93–102.
26. Kuperstein R, Hanly P, Niroumand M, et al. The importance of age and obesity on the relation between diabetes and left ventricular mass. J Am Coll Cardiol. 2001;37:1957–1962.
27. Lauer MS, Evans JC, Levy D. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol. 1992;70:1180–1184.
28. Aurigemma GP, Zile MR, Gaasch WH. Contractile behavior of the left ventricle in diastolic heart failure:with emphasis on regional systolic function. Circulation. 2006;113:296–304.
29. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259.
30. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. Jama. 2006;296:2209–2216.
31. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction:insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation. 2009;119:3070–3077.
32. Lenzen MJ, Scholte Op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function:a report from the Euroheart failure survey. Eur Heart J. 2004;25:1214–1220.
33. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004;55:373–394.
34. Triposkiadis F, Giamouzis G, Parissis J, et al. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail. 2016;18:744–758.
35. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure:a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart failure and echocardiography associations of the European society of cardiology. Eur Heart J. 2007;28:2539–2550.• Relevance of diastolic heart failure in obesity.
36. Russo C, Jin Z, Homma S, et al. Effect of obesity and overweight on left ventricular diastolic function:a community-based study in an elderly cohort. J Am Coll Cardiol. 2011;57:1368–1374.
37. Gonzalez-Quesada C, Cavalera M, Biernacka A, et al. Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. Circ Res. 2013;113:1331–1344.
38. Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis:pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res. 2014;164:323–335.
39. Zhi H, Luptak I, Alreja G, et al. Effects of direct Renin inhibition on myocardial fibrosis and cardiac fibroblast function. PLoS One. 2013;8:e81612.
40. Schorb W, Booz GW, Dostal DE, et al. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res. 1993;72:1245–1254.
41. Sadoshima J, Izumo S. Molecular characterization of angiotensin II–induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993;73:413–423.
42. Crabos M, Roth M, Hahn AW, et al. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest. 1994;93:2372–2378.
43. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction:comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271.
44. Belin de Chantemele EJ, Mintz JD, Rainey WE, et al. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension. 2011;58:271–279.
45. Konishi M, Sugiyama S, Sugamura K, et al. Accumulation of pericardial fat correlates with left ventricular diastolic dysfunction in patients with normal ejection fraction. J Cardiol. 2012;59:344–351.
46. Goodwin GW, Taylor CS, Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem. 1998;273:29530–29539.
47. How OJ, Aasum E, Kunnathu S, et al. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts. Am J Physiol Heart Circ Physiol. 2005;288:H2979–H2985.
48. Rider OJ, Cox P, Tyler D, et al. Myocardial substrate metabolism in obesity. Int J Obes (Lond). 2013;37:972–979.
49. Turer AT, Hill JA, Elmquist JK, et al. Adipose tissue biology and cardiomyopathy:translational implications. Circ Res. 2012;111:1565–1577.
50. Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol. 2010;55:283–293.
51. Ebong IA, Goff DC, Jr., Rodriguez CJ, et al. Mechanisms of heart failure in obesity. Obes Res Clin Pract. 2014;8:e540–e548.
52. Wong C, Marwick TH. Obesity cardiomyopathy:pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med. 2007;4:436–443.
53. Banerjee S, Peterson LR. Myocardial metabolism and cardiac performance in obesity and insulin resistance. Curr Cardiol Rep. 2007;9:143–149.
54. Schaffer JE. Lipotoxicity:when tissues overeat. Curr Opin Lipidol. 2003;14:281–287.
55. Iacobellis G. Epicardial and pericardial fat:close, but very different. Obesity (Silver Spring). 2009;17:625–627.
56. Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans:in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49:417–423.
57. Iacobellis G, Pond CM, Sharma AM. Different “weight” of cardiac and general adiposity in predicting left ventricle morphology. Obesity (Silver Spring). 2006;14:1679–1684.
58. Marchington JM, Pond CM. Site-specific properties of pericardial and epicardial adipose tissue:the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro. Int J Obes. 1990;14:1013–1022.
59. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol. 2015;11:363–371.
60. Balsaver AM, Morales AR, Whitehouse FW. Fat infiltration of myocardium as a cause of cardiac conduction defect. Am J Cardiol. 1967;19:261–265.
61. Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab. 2012;15:805–812.
62. D’Souza K, Nzirorera C, Kienesberger PC. Lipid metabolism and signaling in cardiac lipotoxicity. Biochim Biophys Acta. 2016;1860:1513–1524.
63. Unger RH. Lipotoxic diseases. Annu Rev Med. 2002;53:319–336.
64. Fukushima A, Lopaschuk GD. Cardiac fatty acid oxidation in heart failure associated with obesity and diabetes. Biochim Biophys Acta. 2016;1860:1525–1534.
65. Tang H, Wang Y, Nicholson JK, et al. Use of relaxation-edited one-dimensional and two dimensional nuclear magnetic resonance spectroscopy to improve detection of small metabolites in blood plasma. Anal Biochem. 2004;325:260–272.
66. Tenori L, Hu X, Pantaleo P, et al. Metabolomic fingerprint of heart failure in humans:a nuclear magnetic resonance spectroscopy analysis. Int J Cardiol. 2013;168:e113–e115.
67. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560–563.
68. Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356–362.
69. Grassi G, Seravalle G, Dell’Oro R, et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000;36:538–542.
70. Grassi G, Seravalle G, Quarti-Trevano F, et al. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome:characteristics and mechanisms. Hypertension. 2007;49:535–541.
71. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–2180.
72. Abed HS, Samuel CS, Lau DH, et al. Obesity results in progressive atrial structural and electrical remodeling:implications for atrial fibrillation. Heart Rhythm. 2013;10:90–100.
73. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81:627–635.
74. Koppo K, Siklova-Vitkova M, Klimcakova E, et al. Catecholamine and insulin control of lipolysis in subcutaneous adipose tissue during long-term diet-induced weight loss in obese women. Am J Physiol Endocrinol Metab. 2012;302:E226–E232.
75. Qi Z, Ding S. Obesity-associated sympathetic overactivity in children and adolescents:the role of catecholamine resistance in lipid metabolism. J Pediatr Endocrinol Metab. 2016;29:113–125.
76. Jocken JW, Blaak EE. Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. Physiol Behav. 2008;94:219–230.
77. Frikke-Schmidt H, O’Rourke RW, Lumeng CN, et al. Does bariatric surgery improve adipose tissue function? Obes Rev. 2016;17:795–809.
78. Iso T, Arai M, Wada A, et al. Humoral factor(s) produced by pressure overload enhance cardiac hypertrophy and natriuretic peptide expression. Am J Physiol. 1997;273:H113–H118.
79. Hall C. NT-ProBNP:the mechanism behind the marker. J Card Fail. 2005;11:S81–S83.
80. Hammerer-Lercher A, Neubauer E, Muller S, et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta. 2001;310:193–197.
81. Fisher C, Berry C, Blue L, et al. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart. 2003;89:879–881.
82. Kovacova Z, Tharp WG, Liu D, et al. Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes. Obesity (Silver Spring). 2016;24:820–828.
83. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594–600.
84. Daniels LB, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the breathing not properly multinational study. Am Heart J. 2006;151:999–1005.
85. Asferg CL, Nielsen SJ, Andersen UB, et al. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. Hypertension. 2013;62:147–153.
86. Martin J, Bergeron S, Pibarot P, et al. Impact of bariatric surgery on N-terminal fragment of the prohormone brain natriuretic peptide and left ventricular diastolic function. Can J Cardiol. 2013;29:969–975.•• Effects of bariatric surgery on cardiac structure and function as well as in natriuretic peptide levels.
87. Cheng S, Fox CS, Larson MG, et al. Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. Am J Cardiol. 2011;108:979–984.
88. McMurray RW, Jr., Vesely DL. Weight reduction decreases atrial natriuretic factor and blood pressure in obese patients. Metabolism. 1989;38:1231–1237.• Effect of mild weight loss on natriuretic peptide concentrations.
89. Chainani-Wu N, Weidner G, Purnell DM, et al. Relation of B-type natriuretic peptide levels to body mass index after comprehensive lifestyle changes. Am J Cardiol. 2010;105:1570–1576.
90. Ahmad T, Fiuzat M, Mark DB, et al. The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. Am Heart J. 2014;167:193–202.
91. Bertoni AG, Wagenknecht LE, Kitzman DW, et al. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring). 2012;20:1511–1518.
92. Taner ED, Yavuz B, Okhan AK, et al. An obesity drug sibutramine reduces brain natriuretic peptide (BNP) levels in severely obese patients. Int J Clin Pract. 2010;64:518–522.
93. St Peter JV, Hartley GG, Murakami MM, et al. B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure:relationship to body mass index and gastric bypass surgery. Clin Chem. 2006;52:680–685.
94. Abrahamsson N, Engstrom BE, Sundbom M, et al. Gastric bypass surgery elevates NT-ProBNP levels. Obes Surg. 2013;23:1421–1426.•• Effects of bariatric surgery on cardiac structure and function as well as in natriuretic peptide levels.
95. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction:results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011;4:324–331.
96. Kenchaiah S, Pocock SJ, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure:insights from the Candesartan in heart failure:assessment of reduction in mortality and morbidity (CHARM) program. Circulation. 2007;116:627–636.
97. Gupta A, Braunwald E, McNulty S, et al. Obesity and the response to intensified diuretic treatment in decompensated heart failure:a DOSE trial substudy. J Card Fail. 2012;18:837–844.
98. Gaddam KK, Ventura HO, Lavie CJ. Metabolic syndrome and heart failure–the risk, paradox, and treatment. Curr Hypertens Rep. 2011;13:142–148.
99. Lavie CJ, Sharma A, Alpert MA, et al. Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis. 2016;58:393–400.
100. Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015;115:1428–1434.
101. Clark AL, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis. 2014;56:409–414.
102. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63:2985–3023.
103. Falken Y, Hellstrom PM, Holst JJ, et al. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery:role of gut peptides. J Clin Endocrinol Metab. 2011;96:2227–2235.
104. Borg CM, Le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93:210–215.
105. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–2693.
106. Sjostrom L, Gummesson A, Sjostrom CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study):a prospective, controlled intervention trial. Lancet Oncol. 2009;10:653–662.
107. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–752.
108. Garza CA, Pellikka PA, Somers VK, et al. Structural and functional changes in left and right ventricles after major weight loss following bariatric surgery for morbid obesity. Am J Cardiol. 2010;105:550–556.
109. Owan T, Avelar E, Morley K, et al. Favorable changes in cardiac geometry and function following gastric bypass surgery:2-year follow-up in the Utah obesity study. J Am Coll Cardiol. 2011;57:732–739.
110. Valezi AC, Machado VH. Morphofunctional evaluation of the heart of obese patients before and after bariatric surgery. Obes Surg. 2011;21:1693–1697.
111. Popescu WM, Bell R, Duffy AJ, et al. A pilot study of patients with clinically severe obesity undergoing laparoscopic surgery:evidence for impaired cardiac performance. J Cardiothorac Vasc Anesth. 2011;25:943–949.
112. Masoomi H, Buchberg B, Reavis KM, et al. Factors predictive of venous thromboembolism in bariatric surgery. Am Surg. 2011;77:1403–1406.
113. Gupta PK, Gupta H, Kaushik M, et al. Predictors of pulmonary complications after bariatric surgery. Surg Obes Relat Dis. 2012;8:574–581.
114. Benotti P, Wood GC, Winegar DA, et al. Risk factors associated with mortality after Roux-en-Y gastric bypass surgery. Ann Surg. 2014;259:123–130.
115. Leichman JG, Wilson EB, Scarborough T, et al. Dramatic reversal of derangements in muscle metabolism and left ventricular function after bariatric surgery. Am J Med. 2008;121:966–973.
116. Ippisch HM, Inge TH, Daniels SR, et al. Reversibility of cardiac abnormalities in morbidly obese adolescents. J Am Coll Cardiol. 2008;51:1342–1348.
117. Mukerji R, Petruc M, Fresen JL, et al. Effect of weight loss after bariatric surgery on left ventricular mass and ventricular repolarization in normotensive morbidly obese patients. Am J Cardiol. 2012;110:415–419.
118. Algahim MF, Lux TR, Leichman JG, et al. Progressive regression of left ventricular hypertrophy two years after bariatric surgery. Am J Med. 2010;123:549–555.
119. Leichman JG, Aguilar D, King TM, et al. Improvements in systemic metabolism, anthropometrics, and left ventricular geometry 3 months after bariatric surgery. Surg Obes Relat Dis. 2006;2:592–599.
120. Alsabrook GD, Goodman HR, Alexander JW. Gastric bypass for morbidly obese patients with established cardiac disease. Obes Surg. 2006;16:1272–1277.
121. Johnson BL, Blackhurst DW, Latham BB, et al. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg. 2013;216:545–556.
122. Miranda WR, Batsis JA, Sarr MG, et al. Impact of bariatric surgery on quality of life, functional capacity, and symptoms in patients with heart failure. Obes Surg. 2013;23:1011–1015.
123. Shimada YJ, Tsugawa Y, Brown DF, et al. Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation:population-based, self-controlled series. J Am Coll Cardiol. 2016;67:895–903.
124. McCloskey CA, Ramani GV, Mathier MA, et al. Bariatric surgery improves cardiac function in morbidly obese patients with severe cardiomyopathy. Surg Obes Relat Dis. 2007;3:503–507.
125. Ramani GV, McCloskey C, Ramanathan RC, et al. Safety and efficacy of bariatric surgery in morbidly obese patients with severe systolic heart failure. Clin Cardiol. 2008;31:516–520.•• Effects of bariatric surgery in the context of systolic heart failure.
126. Lim CP, Fisher OM, Falkenback D, et al. Bariatric surgery provides a “bridge to transplant” for morbidly obese patients with advanced heart failure and may obviate the need for transplantation. Obes Surg. 2016;26:486–493.
127. Vest AR, Patel P, Schauer PR, et al. Clinical and echocardiographic outcomes after bariatric surgery in obese patients with left ventricular systolic dysfunction. Circ Heart Fail. 2016;9:e002260.•• Effects of bariatric surgery in the context of systolic heart failure.
128. Woods P, Paquette C, Martin J, et al. Metabolic and cardiovascular improvements after biliopancreatic diversion in a severely obese patient. Cardiovasc Diabetol. 2004;3:5.
129. Taylor TV, Bozkurt B, Shayani P, et al. End-stage cardiac failure in a morbidly obese patient treated by biliopancreatic diversion and cardiac transplantation. Obes Surg. 2002;12:416–418.
130. Ristow B, Rabkin J, Haeusslein E. Improvement in dilated cardiomyopathy after bariatric surgery. J Card Fail. 2008;14:198–202.
131. Gill RS, Karmali S, Nagandran J, et al. Combined ventricular assist device placement with adjustable gastric band (VAD-BAND):a promising new technique for morbidly obese patients awaiting potential cardiac transplantation. J Clin Med Res. 2012;4:127–129.
132. Samaras K, Connolly SM, Lord RV, et al. Take heart:bariatric surgery in obese patients with severe heart failure. Two case reports. Heart Lung Circ. 2012;21:847–849.
133. Caceres M, Czer LS, Esmailian F, et al. Bariatric surgery in severe obesity and end-stage heart failure with mechanical circulatory support as a bridge to successful heart transplantation:a case report. Transplant Proc. 2013;45:798–799.
134. Jeng EI, Aranda JM, Jr., Ahmed M, et al. Left ventricular assist device and bariatric surgery:a bridge to heart transplant by weight and waiting time reduction. J Card Surg. 2016;31:120–122.
135. Hoefnagel AL, Pasternak R, Curle AE, et al. Laparoscopic gastric bypass in a patient with an implanted left ventricular assist device. J Cardiothorac Vasc Anesth. 2012;26:880–882.
136. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates:2006 update–a consensus report from the pulmonary scientific council of the international society for heart and lung transplantation. J Heart Lung Transplant. 2006;25:745–755.
137. Vest AR, Wu Y, Hachamovitch R, et al. The heart failure overweight/obesity survival paradox:the missing sex link. JACC Heart Fail. 2015;3:917–926.
138. Lavie CJ, Ventura HO. The obesity paradox in heart failure:is it all about fitness, fat, or sex? JACC Heart Fail. 2015;3:927–930.
139. Perrone-Filardi P, Paolillo S, Costanzo P, et al. The role of metabolic syndrome in heart failure. Eur Heart J. 2015;36:2630–2634.
140. Pozzo J, Fournier P, Lairez O, et al. Obesity paradox:origin and best way to assess severity in patients with systolic HF. Obesity (Silver Spring). 2015;23:2002–2008.
141. Pandey A, Berry JD, Lavie CJ. Cardiometabolic disease leading to heart failure:better fat and fit than lean and lazy. Curr Heart Fail Rep. 2015;12:302–308.
142. Gupta PP, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Can J Cardiol. 2015;31:195–202.
143. Wannamethee SG, Atkins JL. Muscle loss and obesity:the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc. 2015;74:405–412.
144. Lavie CJ, De SA, Alpert MA, et al. Obesity paradox, cachexia, frailty, and heart failure. Heart Fail Clin. 2014;10:319–326.
145. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure:an Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68:1476–1488.